Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021 - Market to Grow at a CAGR of 21.72%

| Source: Research and Markets Research and Markets

Dublin, Nov. 28, 2017 (GLOBE NEWSWIRE) -- The "Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021" report has been added to Research and Markets' offering.

The global nanoparticles market in biotechnology and pharmaceutical sectors to grow at a CAGR of 21.72% during the period 2017-2021.

The report covers the present scenario and the growth prospects of the global nanoparticles market in biotechnology and pharmaceutical sectors for 2017-2021. To calculate the market size, the report considers the revenue generated from the retail sales of nanoparticles in the aforesaid sectors. The report also includes a discussion of the key vendors operating in this market.

According to the report, one of the major drivers for this market is Rising R&D expenditure in pharmaceutical and biotechnology sectors. The pharmaceutical industry is witnessing a global surge in research funding to combat various rare diseases developing globally or to explore new therapies for existing conditions. The pharmaceutical R&D spending is expected to increase by 4% between 2016 to 2022. Biotechnology companies are also making increased investments in R&D. The US was the largest investor in biotechnology R&D in 2015 investing around $28 billion. France was the second largest investor in biotechnology R&D in 2015 investing over $3.6 billion, followed by Switzerland investing over $2.8 billion. South Korea was the largest investor in biotechnology R&D in Asia, investing over $1.7 billion.

The latest trend gaining momentum in the market is Increasing demand for nanoparticles in stem cell therapy. Stem cells have the remarkable potential of developing into different cell types in the body during early life and growth. Stem cells function as an internal repair system that divides to replenish other cells so long the animal or person is alive. Stem cells include embryonic stem cells and non-embryonic adult stem cells that are unspecialized cells. Advancements in stem cell research expose the tremendous potential of stem cells that can change the face of diseases and how we perceive them.

Further, the report states that one of the major factors hindering the growth of this market is Challenges in development of nanoparticles for therapeutics. Although nanoparticle-based therapeutics overcome biological barriers by effectively delivering hydrophobic drugs at preferentially target sites of disease, only a small number of nanoparticle-based medicines have been approved for clinical use. Manufacturers of nanoparticles face numerous challenges and hurdles at different stages of product development. The complexity of nanoparticles requires careful design and engineering for their three-dimensional construction. Their development requires detailed analysis of orthogonal methods, pharmacological profiles, and biological behaviors. Nanoparticles require detailed characterization and the successful manufacture of these complex constructs.

Key vendors

  • F. Hoffmann-La Roche
  • GE Healthcare
  • Merck
  • Novartis

Other prominent vendors

  • AMAG Pharmaceuticals
  • Amgen
  • Bausch & Lomb
  • Biogen
  • Celgene
  • Gilead
  • Ipsen
  • Leadiant Biosciences
  • nanoComposix
  • Pacira Pharmaceuticals
  • Pfizer
  • Shire
  • UCB

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market size and forecast
  • Five forces analysis

PART 06: MARKET SEGMENTATION BY END-USER

  • Comparison by end-user
  • Biotechnology
  • Pharmaceutical
  • Market opportunity by end-user

PART 07: REGIONAL LANDSCAPE

  • Regional comparison
  • Nanoparticles market in biotechnology and pharmaceutical sectors in Americas
  • Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA
  • Nanoparticles market in biotechnology and pharmaceutical sectors in APAC
  • Market opportunity

PART 08: DECISION FRAMEWORK

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

  • Increasing demand for nanoparticles in stem cell therapy
  • Increasing prevalence of chronic diseases
  • Increasing use of gold nanoparticles

PART 11: VENDOR LANDSCAPE

  • Competitive scenario
  • Investment opportunity

PART 12: VENDOR ANALYSIS

  • Vendor overview
  • Merck
  • F. Hoffmann-La Roche
  • GE Healthcare
  • Novartis
  • Other prominent vendors

PART 13: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/457rxf/global


            











    

        

        
Contact Data